CA3288951A1 - Anticorps anti-ror1 et conjugué anticorps-médicament associé - Google Patents

Anticorps anti-ror1 et conjugué anticorps-médicament associé

Info

Publication number
CA3288951A1
CA3288951A1 CA3288951A CA3288951A CA3288951A1 CA 3288951 A1 CA3288951 A1 CA 3288951A1 CA 3288951 A CA3288951 A CA 3288951A CA 3288951 A CA3288951 A CA 3288951A CA 3288951 A1 CA3288951 A1 CA 3288951A1
Authority
CA
Canada
Prior art keywords
seq
set forth
variable region
chain variable
math
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3288951A
Other languages
English (en)
Inventor
Jie Zhu
Xiaobei ZHAO
Zhenhua Wu
Lei Nie
Xiaofen MEI
Xinzeng Wang
Xiaoze WANG
Chenxiao PAN
Yaqiong ZHOU
Gang Chen
Haibin WANG
Original Assignee
Bioray Pharmaceutical Co Ltd
Bioray Pharmaceutical Hangzhou co Ltd
Bioray Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioray Pharmaceutical Co Ltd, Bioray Pharmaceutical Hangzhou co Ltd, Bioray Pharmaceutical Corp filed Critical Bioray Pharmaceutical Co Ltd
Publication of CA3288951A1 publication Critical patent/CA3288951A1/fr
Pending legal-status Critical Current

Links

CA3288951A 2023-04-11 2024-04-11 Anticorps anti-ror1 et conjugué anticorps-médicament associé Pending CA3288951A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310381704.7 2023-04-11

Publications (1)

Publication Number Publication Date
CA3288951A1 true CA3288951A1 (fr) 2026-01-19

Family

ID=

Similar Documents

Publication Publication Date Title
AU2018270961B9 (en) Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
JP2024535637A (ja) 抗体及びその薬物コンジュゲ－ト並びに用途
JP6701162B2 (ja) Ａｘｌに結合する抗体
JP2022037170A (ja) 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート
KR20220017946A (ko) 항-b7-h4 항체-약물 접합체 및 이의 의학적 용도
KR102458196B1 (ko) 항-axl 길항성 항체
JP7401456B2 (ja) 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CN110382535A (zh) 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
EP4696329A1 (fr) Anticorps anti-ror1 et conjugué anticorps-médicament associé
IL314567A (en) Drug-conjugated antibody to HER3 and its use
JP2024503658A (ja) 抗ｄｌｌ３抗体－薬物コンジュゲート
US20250333541A1 (en) Antibody, and drug conjugate and use thereof
US20240228658A1 (en) Anti-5t4 antibodies and uses thereof
CN118791622A (zh) 抗ror1抗体及其药物偶联物
CA3288951A1 (fr) Anticorps anti-ror1 et conjugué anticorps-médicament associé
WO2026077395A1 (fr) Thérapie de combinaison impliquant un conjugué anticorps-médicament anti-ror1
US20250129175A1 (en) CDC Platform Antibody
WO2026077396A1 (fr) Traitement du cancer pharmacorésistant à base de conjugué anticorps-médicament anti-ror1
WO2026057074A1 (fr) Thérapie de combinaison avec un conjugué anticorps-médicament anti-liv-1
WO2025242039A1 (fr) Anticorps anti-cdh17, conjugué anticorps-médicament associé et son utilisation
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
KR20260053355A (ko) 화합물 및 이를 포함하는 항체 약물 접합체
HK40127994A (zh) 抗cdh17抗体、其抗体药物偶联物及其用途
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos